(Q46389656)

21 December 2017

title

Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory (English)

1 reference

21 December 2017

1

Charles M Strom

1 reference

21 December 2017

author name string

Dana Goos

2

1 reference

21 December 2017

Beryl Crossley

3

1 reference

21 December 2017

Ke Zhang

4

1 reference

21 December 2017

Arlene Buller-Burkle

5

1 reference

21 December 2017

Michael Jarvis

6

1 reference

21 December 2017

Franklin Quan

7

1 reference

21 December 2017

Mei Peng

8

1 reference

21 December 2017

Weimin Sun

9

1 reference

21 December 2017

language of work or name

English

0 references

publication date

7 October 2011

1 reference

21 December 2017

published in

Genetics in Medicine

1 reference

21 December 2017

volume

14

1 reference

21 December 2017

issue

1

1 reference

21 December 2017

page(s)

95-100

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1038/gim.0b013e3182329870

exact match

0 references

cites work

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidog

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic determinants of platelet response to clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic determinants of on-clopidogrel high platelet reactivity.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

CYP2C19*17 is associated with decreased breast cancer risk

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness

1 reference

https://api.crossref.org/works/10.1038%2FGIM.0B013E3182329870

7 January 2021

10.1038/GIM.0B013E3182329870

Identifiers

DOI

1 reference

21 December 2017

Microsoft Academic ID

2094119604

0 references

1 reference

21 December 2017